drugset / Trial / NCT01426867

A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2%

NCT01426867

Phase 2 Completed 103 enrolled Alcon Research
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study was to describe the ocular discomfort immediately upon instillation of Brinzolamide 1%/Brimonidine 0.2% Tartrate Ophthalmic Suspension, Brinzolamide 1% Ophthalmic Suspension, and Brimonidine Tartrate 0.2% Ophthalmic Solution in subjects with open-angle glaucoma and/or ocular hypertension.

Timeline

Start
2011-09
Primary completion
2011-11
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Brimonidine Small molecule 0.2 % Other
Subject Brinzolamide Small molecule 1 % Other